DK3484514T3 - Compositions and methods related to engineered fc constructs - Google Patents

Compositions and methods related to engineered fc constructs Download PDF

Info

Publication number
DK3484514T3
DK3484514T3 DK17803463.3T DK17803463T DK3484514T3 DK 3484514 T3 DK3484514 T3 DK 3484514T3 DK 17803463 T DK17803463 T DK 17803463T DK 3484514 T3 DK3484514 T3 DK 3484514T3
Authority
DK
Denmark
Prior art keywords
engineered
constructs
compositions
methods related
methods
Prior art date
Application number
DK17803463.3T
Other languages
English (en)
Inventor
Carlos J Bosques
Jonathan C Lansing
Nathanial J Washburn
Daniel Ortiz
Laura Rutitzky
Original Assignee
Momenta Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Momenta Pharmaceuticals Inc filed Critical Momenta Pharmaceuticals Inc
Application granted granted Critical
Publication of DK3484514T3 publication Critical patent/DK3484514T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0684—Cells of the urinary tract or kidneys
    • C12N5/0686—Kidney cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • General Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK17803463.3T 2016-05-23 2017-05-23 Compositions and methods related to engineered fc constructs DK3484514T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662340322P 2016-05-23 2016-05-23
US201762443451P 2017-01-06 2017-01-06
PCT/US2017/034084 WO2017205434A1 (en) 2016-05-23 2017-05-23 Compositions and methods related to engineered fc constructs

Publications (1)

Publication Number Publication Date
DK3484514T3 true DK3484514T3 (da) 2024-01-29

Family

ID=60412547

Family Applications (1)

Application Number Title Priority Date Filing Date
DK17803463.3T DK3484514T3 (da) 2016-05-23 2017-05-23 Compositions and methods related to engineered fc constructs

Country Status (13)

Country Link
US (4) US11155640B2 (da)
EP (2) EP3484514B1 (da)
JP (4) JP2019519527A (da)
KR (3) KR102462084B1 (da)
CN (3) CN116063540A (da)
AU (2) AU2017272111B2 (da)
BR (2) BR112018074032A2 (da)
CA (2) CA3025310A1 (da)
DK (1) DK3484514T3 (da)
IL (3) IL309293A (da)
PL (1) PL3484514T3 (da)
SG (3) SG10202011624SA (da)
WO (2) WO2017205434A1 (da)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG10201913507SA (en) 2014-05-02 2020-02-27 Momenta Pharmaceuticals Inc Compositions and methods related to engineered fc constructs
KR102462084B1 (ko) 2016-05-23 2022-11-02 모멘타 파머슈티컬스 인코포레이티드 유전자 조작 Fc 작제물에 관한 조성물 및 방법
CN110650748B (zh) * 2017-01-06 2024-01-02 动量制药公司 与经工程改造的Fc构建体相关的组合物和方法
CN113395978A (zh) * 2018-07-11 2021-09-14 动量制药公司 与靶向CTLA-4的工程化Fc-抗原结合结构域构建体有关的组合物和方法
CA3106142A1 (en) * 2018-07-11 2020-01-16 Momenta Pharmaceuticals, Inc. Compositions and methods related to engineered fc-antigen binding domain constructs targeted to cd38
JP2021531757A (ja) * 2018-07-11 2021-11-25 モメンタ ファーマシューティカルズ インコーポレイテッド 改変されたＦｃ−抗原結合ドメイン構築体に関する組成物および方法
BR112021000391A2 (pt) * 2018-07-11 2021-04-06 Momenta Pharmaceuticals, Inc. Composições e métodos relacionados a construtos do domínio de ligação fc-antígeno manipulado direcionado a ccr4
US20210317227A1 (en) * 2018-07-11 2021-10-14 Momenta Pharmaceuticals, Inc. COMPOSITIONS AND METHODS RELATED TO ENGINEERED Fc-ANTIGEN BINDING DOMAIN CONSTRUCTS
MX2021000287A (es) * 2018-07-11 2021-09-08 Momenta Pharmaceuticals Inc Composiciones y métodos relacionados con constructos de dominio de unión a antígeno-fc modificados genéticamente.
US20210284717A1 (en) * 2018-07-11 2021-09-16 Momenta Pharmaceuticals, Inc. Compositions and methods related to engineered fc-antigen binding domain constructs
WO2020014419A2 (en) * 2018-07-11 2020-01-16 Momenta Pharmaceuticals Inc Compositions and methods related to engineered fc-antigen binding domain constructs targeted to pd-l1
KR102661494B1 (ko) 2019-03-08 2024-04-29 에이치엘만도 주식회사 랙구동형 동력 보조 조향장치
AU2020344164A1 (en) 2019-09-13 2022-04-14 CSL Behring Lengnau AG Recombinant IgG Fc multimers for the treatment of immune complex-mediated kidney disorders
KR20220110818A (ko) 2019-12-06 2022-08-09 체에스엘 베링 렝나우 아게 Fc 다량체의 안정한 조성물
CN111808170A (zh) * 2020-06-29 2020-10-23 江苏为真生物医药技术股份有限公司 多肽、hla-dr蛋白及其制备方法和应用
EP4255933A1 (en) * 2020-12-07 2023-10-11 Invetx, Inc. Compositions for increasing half-life of a therapeutic agent in livestock animals and methods of use

Family Cites Families (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2556219B1 (fr) 1983-12-07 1987-06-26 Merieux Inst Nouveau medicament immunomodulateur, a base de fragments fc d'igg humaines
US5426641A (en) 1994-01-28 1995-06-20 Bell Communications Research, Inc. Adaptive class AB amplifier for TDMA wireless communications systems
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
AU3804397A (en) 1996-06-14 1998-01-07 Smithkline Beecham Corporation Hexameric fusion proteins and uses therefor
US20090074839A1 (en) 1997-01-22 2009-03-19 Marton Milankovits Pharmaceutical Compositions Primarily for the Treatment and Prevention of Genitourinary Infections and their Extragenital Complications
US7951917B1 (en) * 1997-05-02 2011-05-31 Genentech, Inc. Method for making multispecific antibodies having heteromultimeric and common components
US20020062010A1 (en) * 1997-05-02 2002-05-23 Genentech, Inc. Method for making multispecific antibodies having heteromultimeric and common components
US6737056B1 (en) * 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
EP1240337B1 (en) 1999-12-24 2006-08-23 Genentech, Inc. Methods and compositions for prolonging elimination half-times of bioactive compounds
US20050089932A1 (en) 2001-04-26 2005-04-28 Avidia Research Institute Novel proteins with targeted binding
US20050249723A1 (en) 2003-12-22 2005-11-10 Xencor, Inc. Fc polypeptides with novel Fc ligand binding sites
JP5620626B2 (ja) 2005-03-31 2014-11-05 中外製薬株式会社 会合制御によるポリペプチド製造方法
GB0614780D0 (en) 2006-07-25 2006-09-06 Ucb Sa Biological products
US7825093B2 (en) 2006-10-25 2010-11-02 Amgen Inc. Methods of using OSK1 peptide analogs
BRPI0620639A2 (pt) 2006-12-21 2011-11-22 Micromet Ag anticorpos de cadeia simples biespecìficos e composição farmacêutica compreendendo os mesmos
US20080260738A1 (en) 2007-04-18 2008-10-23 Moore Margaret D Single chain fc, methods of making and methods of treatment
US20090252729A1 (en) 2007-05-14 2009-10-08 Farrington Graham K Single-chain Fc (scFc) regions, binding polypeptides comprising same, and methods related thereto
CA2688490C (en) 2007-06-01 2022-06-21 Scott E. Strome Immunoglobulin constant region fc receptor binding agents
PL2235064T3 (pl) 2008-01-07 2016-06-30 Amgen Inc Sposób otrzymywania cząsteczek przeciwciał z heterodimerycznymi fc z zastosowaniem kierujących efektów elektrostatycznych
JP5555223B2 (ja) 2008-04-02 2014-07-23 マクロジェニクス，インコーポレーテッド ＨＥＲ２／ｎｅｕ特異的抗体およびその使用方法
JP2012504660A (ja) 2008-10-06 2012-02-23 ユニバーシティ オブ シカゴ 細菌ｅａｐ、ｅｍｐおよび／またはａｄｓａタンパク質に関連する組成物および方法
US20100143353A1 (en) 2008-12-04 2010-06-10 Mosser David M POLYPEPTIDES COMPRISING Fc FRAGMENTS OF IMMUNOGLOBULIN G (lgG) AND METHODS OF USING THE SAME
US10865233B2 (en) 2008-12-18 2020-12-15 Dana-Farber Cancer Institute, Inc. NKG2D-fc for immunotherapy
MX2011007833A (es) 2009-01-23 2011-10-06 Biogen Idec Inc Polipeptidos fc estabilizados con funcion efectora reducida y metodos de uso.
WO2010135534A2 (en) 2009-05-20 2010-11-25 Children's Medical Center Corporation Compositions for the treatment of metastatic cancer and methods of use thereof
US8858948B2 (en) 2009-05-20 2014-10-14 Theraclone Sciences, Inc. Compositions and methods for the therapy and diagnosis of influenza
JP5683581B2 (ja) * 2009-06-30 2015-03-11 リサーチ ディベロップメント ファウンデーション 免疫グロブリンＦｃポリペプチド
SG179196A1 (en) 2009-09-16 2012-04-27 Genentech Inc Coiled coil and/or tether containing protein complexes and uses thereof
AU2010303415B2 (en) 2009-10-07 2015-02-19 Macrogenics, Inc. Fc region-containing polypeptides that exhibit improved effector function due to alterations of the extent of fucosylation, and methods for their use
ES2688978T3 (es) 2009-11-23 2018-11-07 Amgen Inc. Anticuerpo monomérico Fc
GB0922209D0 (en) 2009-12-18 2010-02-03 Univ Nottingham Proteins, nucleic acid molecules and compositions
WO2011146902A1 (en) 2010-05-21 2011-11-24 Merrimack Pharmaceuticals, Inc. Bi-specific fusion proteins
EA201291482A1 (ru) 2010-07-09 2013-10-30 Байоджен Айдек Хемофилия Инк. Химерные факторы коагуляции
CN105820256A (zh) 2010-07-28 2016-08-03 格利克尼克股份有限公司 天然人蛋白片段的融合蛋白以产生有序多聚化免疫球蛋白fc组合物
AU2011288412A1 (en) 2010-08-13 2013-02-21 Medimmune Limited Monomeric polypeptides comprising variant Fc regions and methods of use
EP2635607B1 (en) 2010-11-05 2019-09-04 Zymeworks Inc. Stable heterodimeric antibody design with mutations in the fc domain
DK2654780T3 (da) * 2010-12-23 2017-04-10 Janssen Biotech Inc Aktive protease-resistente antistof-fc-mutanter
CA2827188C (en) 2011-03-17 2020-02-11 Itai Benhar Bi- and monospecific, asymmetric antibodies and methods of generating the same
CA2812739A1 (en) 2011-03-25 2012-10-04 Glenmark Pharmaceuticals S.A. Hetero-dimeric immunoglobulins
EP3693000B1 (en) 2012-06-08 2022-03-02 Bioverativ Therapeutics Inc. Procoagulant compounds
CN104582736A (zh) 2012-06-21 2015-04-29 印第安纳大学研究及科技有限公司 Fc效应子功能改变的肠降血糖素受体配体多肽Fc区融合多肽和缀合物
US9683044B2 (en) 2012-08-20 2017-06-20 Gliknik Inc. Molecules with antigen binding and polyvalent FC gamma receptor binding activity
JP2015536317A (ja) 2012-10-17 2015-12-21 リバプール・スクール・オブ・トロピカル・メディスン 免疫調節タンパク質
CN104558194B (zh) 2013-10-17 2018-04-27 泰州迈博太科药业有限公司 一类抗CD20-Flex双功能融合蛋白、其制备方法及用途
US10137170B2 (en) 2013-12-20 2018-11-27 Indiana University Research And Technology Corporation Lipidated incretin receptor ligand human immunoglobulin Fc-region fusion polypeptides
KR20160107190A (ko) 2014-01-15 2016-09-13 에프. 호프만-라 로슈 아게 변형된 FcRn-결합 및 유지된 단백질 A-결합 성질을 갖는 Fc-영역 변이체
CN113248613A (zh) 2014-01-15 2021-08-13 豪夫迈·罗氏有限公司 具有修饰的FCRN结合性质的Fc区变体
SG11201606597QA (en) 2014-03-05 2016-09-29 Ucb Biopharma Sprl Multimeric fc proteins
RU2016139022A (ru) 2014-03-05 2018-04-25 Юсб Биофарма Спрл МУЛЬТИМЕРНЫЕ Fc-БЕЛКИ
SG10201913507SA (en) * 2014-05-02 2020-02-27 Momenta Pharmaceuticals Inc Compositions and methods related to engineered fc constructs
NZ726514A (en) * 2014-05-29 2019-01-25 Macrogenics Inc Tri-specific binding molecules and methods of use thereof
EP3423572B1 (en) 2016-03-02 2023-11-29 Momenta Pharmaceuticals, Inc. Methods related to engineered fc constructs
KR102462084B1 (ko) * 2016-05-23 2022-11-02 모멘타 파머슈티컬스 인코포레이티드 유전자 조작 Fc 작제물에 관한 조성물 및 방법
CN110650748B (zh) 2017-01-06 2024-01-02 动量制药公司 与经工程改造的Fc构建体相关的组合物和方法

Also Published As

Publication number Publication date
JP2022068176A (ja) 2022-05-09
BR112018074056A2 (pt) 2019-03-06
CN109789203A (zh) 2019-05-21
KR20190021255A (ko) 2019-03-05
AU2017272111A1 (en) 2019-01-17
EP3464376A4 (en) 2020-03-18
KR20220151025A (ko) 2022-11-11
AU2017272109A1 (en) 2019-01-17
KR20190026684A (ko) 2019-03-13
US20220049019A1 (en) 2022-02-17
CN109963869A (zh) 2019-07-02
IL263211B2 (en) 2023-09-01
SG11201810466PA (en) 2018-12-28
US11155640B2 (en) 2021-10-26
IL263211B1 (en) 2023-05-01
US11623964B2 (en) 2023-04-11
US20240067757A1 (en) 2024-02-29
KR102462084B1 (ko) 2022-11-02
WO2017205434A1 (en) 2017-11-30
IL263211A (en) 2018-12-31
JP7045333B2 (ja) 2022-03-31
IL263213B2 (en) 2024-05-01
JP2019519527A (ja) 2019-07-11
US20190284305A1 (en) 2019-09-19
BR112018074032A2 (pt) 2019-02-26
JP7045333B6 (ja) 2022-05-06
CA3025306A1 (en) 2017-11-30
KR102635635B1 (ko) 2024-02-14
EP3464376A1 (en) 2019-04-10
EP3484514A4 (en) 2020-08-12
AU2017272111B2 (en) 2024-05-16
EP3484514B1 (en) 2023-12-06
WO2017205436A1 (en) 2017-11-30
US20210221917A1 (en) 2021-07-22
SG11201810465RA (en) 2018-12-28
IL309293A (en) 2024-02-01
SG10202011624SA (en) 2021-01-28
IL263213B1 (en) 2024-01-01
CA3025310A1 (en) 2017-11-30
JP2022095685A (ja) 2022-06-28
JP7295301B2 (ja) 2023-06-20
CN109789203B (zh) 2022-08-05
PL3484514T3 (pl) 2024-04-29
EP3484514A1 (en) 2019-05-22
IL263213A (en) 2018-12-31
KR102590061B1 (ko) 2023-10-18
JP2019519528A (ja) 2019-07-11
CN116063540A (zh) 2023-05-05

Similar Documents

Publication Publication Date Title
IL286367A (en) Compositions and methods relating to engineered fc constructs
DK3484514T3 (da) Compositions and methods related to engineered fc constructs
DK3234133T3 (da) Crispr-baserede sammensætninger og fremgangsmåder til anvendelse
BR112017000039A2 (pt) composições agrícolas e aplicações que utilizam óleos essenciais
DK3221363T3 (da) Antistoffer mod cd73 og anvendelser deraf
DK3169741T3 (da) Forbedrede bindemiddelsammensætninger og anvendelser deraf
DK2961831T3 (da) Sammensætninger og fremgangsmåder til immunterapi
DK3116533T3 (da) Deletion af dystrophingenexon under anvendelse af genmanipulerede nukleaser
DK3008168T3 (da) Sc-celler og sammensætninger og fremgangsmåde til dannelse deraf
KR20180084891A (ko) 구조 조성물 및 방법
DK3144001T3 (da) Sammensætninger af selenoorganiske forbindelser og fremgangsmåder til anvendelse deraf
DK3018183T3 (da) Halogenolefinbaseret sammensætning og anvendelse deraf
EP3423572A4 (en) METHODS RELATING TO MANIPULATED FC CONSTRUCTS
BR112016024191A2 (pt) composições e aplicações agrícolas utilizando compostos minerais
DK3194564T3 (da) Trichodermasammensætninger og anvendelsesfremgangsmåder
DK3183295T3 (da) Fraktioneret alkyleret cyclodextrinsammensætning og fremgangsmåder til fremstilling og anvendelse af samme
SG10202107391YA (en) Compositions and methods related to engineered fc constructs
DK3288379T3 (da) Peptidsammensætninger og anvendelsesmåder
BR112017012240A2 (pt) métodos de preparação de composições contendo alcaloides e suas utilizações
DK3113774T3 (da) Sammensætninger af grapiprant og fremgangsmåder til anvendelse deraf
DK3233104T3 (da) Immunterapi-behandlinger og -sammensætninger
DK3068428T3 (da) Annexin-ii-variant-sammensætninger og fremgangsmåder
DK3099314T3 (da) Tolerogene sammensætninger og anvendelser deraf
FR3026639B1 (fr) Composition cosmetique
TH1601001639A (th) องค์ประกอบวัคซีนของ pcv2b แบบไดเวอร์เจนท์ และวิธีการใช้งาน